Welcome to our dedicated page for Cingulate SEC filings (Ticker: CINGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cingulate’s SEC filings aren’t just numbers—they map the path from Precision Timed Release™ research to potential FDA approval. Yet dissecting a biotech 10-K that details trial design, cash burn, and warrant (CINGW) dilution can take hours. Stock Titan’s AI-powered analysis translates the scientific jargon and risk factors into concise takeaways, so you can focus on what matters.
Need to track Cingulate insider trading Form 4 transactions before the next data read-out? Our platform streams Cingulate Form 4 insider transactions real-time, flags option exercises, and links every trade to pipeline milestones. If you are asking, “Where’s the Cingulate quarterly earnings report 10-Q filing?” or want a Cingulate annual report 10-K simplified summary, the documents appear here the moment EDGAR posts—complete with AI highlights of R&D spend and PTR patent updates. We also answer common searches like “Cingulate SEC filings explained simply” and “understanding Cingulate SEC documents with AI.”
Each filing type unlocks a different angle: 8-Ks reveal dosing-study results—see “Cingulate 8-K material events explained.” Proxy statements unpack board expertise and Cingulate proxy statement executive compensation. Our earnings tools provide Cingulate earnings report filing analysis to spot cash-runway changes quarter over quarter. In one dashboard you can:
- Receive AI-generated summaries of 10-K, 10-Q, 8-K and S-1 documents
- Monitor Cingulate executive stock transactions Form 4
- Export red-lined comparisons across reporting periods
Carvana Co. (CVNA) – Form 4 insider transaction
CEO, Chairman and 10% owner Ernest C. Garcia III reported the sale of a cumulative 9,904 Class A shares on 08-09 July 2025 through two family trusts (Ernest Irrevocable 2004 Trust III and Ernest C. Garcia III Multi-Generational Trust III). All trades were executed under a Rule 10b5-1 plan adopted 13-Dec-2024, indicating the transactions were pre-scheduled.
• Price range: $343.43 – $360.03 per share.
• Average price (simple): c.$350.
• Shares remaining: 676,488 (Irrevocable Trust) and 776,488 (Multi-Generational Trust) – a combined ≈1.45 million shares.
• Percentage sold: roughly 0.7 % of the combined trust holdings and an even smaller fraction of Garcia’s overall economic interest in Carvana.
No derivative transactions were reported, and no additional securities were acquired. Garcia retains his roles as Chief Executive Officer, Director and >10 % beneficial owner.
Investor takeaway: The sale is modest relative to Garcia’s total stake and was executed under a pre-planned 10b5-1 program, limiting signaling value. While insider selling can create a negative headline, the small size and structured nature suggest routine diversification rather than a strategic shift.
Affirm Holdings, Inc. (AFRM) – Insider Transaction Form 4
On 07/07/2025, Chief Financial Officer Robert O’Hare reported the sale of 19,802 Class A common shares at a weighted-average price of $70.03 (range $70.00-$70.21) under a Rule 10b5-1 trading plan adopted 12/06/2024. After the sale, the filing lists 0 shares beneficially owned.
- Transaction code: S (open-market sale)
- Form filed on 07/09/2025; only non-derivative shares affected
- No derivative positions were reported
The filing signals full divestiture by the company’s CFO while confirming adherence to SEC 10b5-1 safe-harbor procedures.
Affirm Holdings, Inc. (AFRM) – Insider Transaction Form 4
On 07/07/2025, Chief Financial Officer Robert O’Hare reported the sale of 19,802 Class A common shares at a weighted-average price of $70.03 (range $70.00-$70.21) under a Rule 10b5-1 trading plan adopted 12/06/2024. After the sale, the filing lists 0 shares beneficially owned.
- Transaction code: S (open-market sale)
- Form filed on 07/09/2025; only non-derivative shares affected
- No derivative positions were reported
The filing signals full divestiture by the company’s CFO while confirming adherence to SEC 10b5-1 safe-harbor procedures.
Affirm Holdings, Inc. (AFRM) – Insider Transaction Form 4
On 07/07/2025, Chief Financial Officer Robert O’Hare reported the sale of 19,802 Class A common shares at a weighted-average price of $70.03 (range $70.00-$70.21) under a Rule 10b5-1 trading plan adopted 12/06/2024. After the sale, the filing lists 0 shares beneficially owned.
- Transaction code: S (open-market sale)
- Form filed on 07/09/2025; only non-derivative shares affected
- No derivative positions were reported
The filing signals full divestiture by the company’s CFO while confirming adherence to SEC 10b5-1 safe-harbor procedures.
Affirm Holdings, Inc. (AFRM) – Insider Transaction Form 4
On 07/07/2025, Chief Financial Officer Robert O’Hare reported the sale of 19,802 Class A common shares at a weighted-average price of $70.03 (range $70.00-$70.21) under a Rule 10b5-1 trading plan adopted 12/06/2024. After the sale, the filing lists 0 shares beneficially owned.
- Transaction code: S (open-market sale)
- Form filed on 07/09/2025; only non-derivative shares affected
- No derivative positions were reported
The filing signals full divestiture by the company’s CFO while confirming adherence to SEC 10b5-1 safe-harbor procedures.
Affirm Holdings, Inc. (AFRM) – Insider Transaction Form 4
On 07/07/2025, Chief Financial Officer Robert O’Hare reported the sale of 19,802 Class A common shares at a weighted-average price of $70.03 (range $70.00-$70.21) under a Rule 10b5-1 trading plan adopted 12/06/2024. After the sale, the filing lists 0 shares beneficially owned.
- Transaction code: S (open-market sale)
- Form filed on 07/09/2025; only non-derivative shares affected
- No derivative positions were reported
The filing signals full divestiture by the company’s CFO while confirming adherence to SEC 10b5-1 safe-harbor procedures.
Cingulate Inc. (CING) filed a Form 4 reporting two stock-option grants to Raul R. Silva, EVP & Chief Scientific Officer.
- Grant 1: 1,000 options to buy common stock at an exercise price of $4.30 per share. Grant and first exercisable date: 03/31/2025; expiration: 03/31/2035.
- Grant 2: 1,000 options at an exercise price of $4.07 per share. Grant and first exercisable date: 06/30/2025; expiration: 06/30/2035.
Both grants were made pursuant to Dr. Silva’s employment agreement and are held directly. No open-market purchases or sales of common stock were reported, and Table I shows no changes in non-derivative holdings. Post-transaction, Dr. Silva beneficially owns 1,000 derivative securities in each grant line, representing incentive alignment but a modest absolute share count.
Director Jeffrey S. Ervin of Cingulate has been granted 15,000 stock options on June 20, 2025. The options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at the earlier of:
- One-year anniversary of grant date
- Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing represents a standard director compensation grant, with the options providing Ervin the right to purchase common stock at the specified strike price. The grant aligns the director's interests with shareholders through long-term equity incentives.
Director John A. Roberts of Cingulate was granted 15,000 stock options on June 20, 2025. The stock options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at earlier of: - One-year anniversary of grant date - Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing, signed by Attorney-in-Fact Shane J. Schaffer on June 23, 2025, represents standard non-employee director equity compensation. The options provide Roberts with the right to purchase up to 15,000 shares of Cingulate common stock once vested. This grant aligns the director's interests with those of shareholders through long-term equity ownership potential.
FAQ
What is the current stock price of Cingulate (CINGW)?
What is Cingulate's primary focus?
What is the Precision Timed Release™ (PTR™) platform?
What is Cingulate's lead product candidate?
How does Cingulate differentiate itself in the pharmaceutical market?
What therapeutic areas is Cingulate exploring beyond ADHD?
What is Cingulate's global expansion strategy?
When does Cingulate plan to submit its NDA for CTx-1301?
What challenges does Cingulate face in its market?
How does Cingulate generate revenue?
What is the significance of Cingulate's recent FDA-required study completion?
